Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
neutropenia/protease
Ссылка сохраняется в буфер обмена
Страница 1 от 113 полученные результаты
Serum Concentrations of Mannan-Binding Lectin (MBL) and MBL-Associated Serine Protease-2 and the Risk of Adverse Events in Pediatric Patients With Cancer and Fever in Neutropenia.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
It is unknown whether serum concentrations of mannan-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) influence the risk of adverse events (AEs) in children with cancer presenting with fever in neutropenia (FN).
METHODS
Pediatric patients with cancer presenting with FN
Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
Mannose-binding lectin-associated serine protease-2 (MASP-2) is an essential component of the lectin pathway of complement activation. MASP-2 deficiency is common because of genetic polymorphisms, but its impact on susceptibility to infection is largely unknown. The aim of the present
Protease inhibitors potentiate chemotherapy-induced neutropenia.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Pharmacokinetic interactions between chemotherapy and highly active antiretroviral therapy (HAART) are described, but there are few data on their clinical relevance. Patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) were treated with concomitant HAART and infusional
Editorial: Serine proteases, serpins, and neutropenia.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Neutrophil serine proteases: future therapeutic targets in patients with severe chronic neutropenia and leukemia?
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Nelfinavir is an HIV protease inhibitor being repurposed as an anti-cancer agent in preclinical models and in small oncology trials, yet the MTD of nelfinavir has not been determined. Therefore, we conducted a Phase Ia study to establish the maximum tolerated dose (MTD) and dose limiting toxicities
Stage specific gene expression of serpins and their cognate proteases during myeloid differentiation.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Proteases and their serpin inhibitors are abundantly expressed in haemopoietic and peripheral blood cells. There is, however, relatively little information about the role played by serpins in the control of protease activity within these cells and in the pericellular region. The observation that
Leukemia in severe congenital neutropenia: defective proteolysis suggests new pathways to malignancy and opportunities for therapy.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Severe congenital neutropenia (SCN), a heterogeneous disorder that includes Kostmann syndrome, predisposes to myelodysplasia and acute myelogenous leukemia. Recently identified heterozygous mutations in the gene ELA2, encoding neutrophil elastase on human chromosome 19pter, account for the majority
Kostmann syndrome or infantile genetic agranulocytosis, part two: Understanding the underlying genetic defects in severe congenital neutropenia.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Congenital neutropenia in man was first reported 50 years ago by the Swedish paediatrician Rolf Kostmann. He coined the term 'infantile genetic agranulocytosis' for this condition, which is now known as Kostmann syndrome. Recent studies have revealed mutations in ELA-2, encoding the neutrophil
[Anaemia and neutropenia in a cohort of non-infected children of HIV-positive mothers].
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND
Mother-to-child HIV transmission is currently around 1% in western countries, due to prevention measures. Antiretroviral drugs do have adverse effects, anaemia and myelosupression caused by AZT being the most observed effects. In the present study, we analyse the prevalence of anaemia and
Virulence of Aspergillus fumigatus double mutants lacking restriction and an alkaline protease in a low-dose model of invasive pulmonary aspergillosis.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
To investigate the pathogenicity of Aspergillus fumigatus mutants lacking putative virulence factors, we have developed a new murine model of invasive pulmonary aspergillosis based on neutropenia, the major factor predisposing patients to this infection. Mice were treated with cyclophosphamide and
Boceprevir: a recently approved protease inhibitor for hepatitis C virus infection.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE
The pharmacologic properties, clinical efficacy, and safety profile of the first oral protease inhibitor approved for the treatment of chronic infection with hepatitis C virus (HCV) genotype 1 are reviewed.
CONCLUSIONS
Boceprevir, approved by the Food and Drug Administration as an adjunct
Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE
To evaluates the effectiveness and safety of the first generation, NS3/4A protease inhibitors (PIs) in clinical practice against chronic C virus, especially in patients with advanced fibrosis.
METHODS
Prospective study and non-experimental analysis of a multicentre cohort of 38 Spanish
A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in granulocytic differentiation.
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
We identified diminished levels of the natural inhibitor of neutrophil elastase (NE), secretory leukocyte protease inhibitor (SLPI), in myeloid cells and plasma of patients with severe congenital neutropenia (CN). We further found that downregulation of SLPI in CD34(+) bone marrow (BM) hematopoietic
Самая полная база данных о лекарственных травах, подтвержденная наукой
- Работает на 55 языках
- Травяные лекарства, подтвержденные наукой
- Распознавание трав по изображению
- Интерактивная карта GPS - отметьте травы на месте (скоро)
- Прочтите научные публикации, связанные с вашим поиском
- Ищите лекарственные травы по их действию
- Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов
Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.
